At cellular level, we observed a strong step-wise increase in the percentage of transitional B cells from IFN-β (P = 4.50 x 10-3) to fingolimod (P = 2.59 x 10-15) compared to untreated MS patients (Figure 1A). This evidence concerns the gene IFNB1 and myeloid sarcoma.